Skip to main content
SpringerLink
Log in
Book cover

Die Urologie pp 409–430Cite as

Urothelkarzinom der Nieren und Harnleiter: Therapie

  • Chapter
  • First Online:

  • 418 Accesses

Part of the book series: Springer Reference Medizin ((SRM))

Zusammenfassung

Die Therapie des Urothelkarzinoms des oberen Harntraktes hängt in erster Linie vom Stadium und vom Grading ab. Eine Heilung lässt sich primär nur durch die chirurgische Entfernung erreichen. Zusätzlich können je nach Befund andere Methoden, wie Chemotherapie oder Radiatio adjuvant oder neoadjuvant, notwendig werden. Urothelkarzinome des oberen Harntraktes (UTUC) machen etwa 8–10 % der Urothelkarzinome aus, und damit ist die Behandlung der metastasierten Erkrankung weitgehend aus den Behandlungsparadigmen des metastasierten Blasenkarzinoms extrapoliert. Ein multimodaler Ansatz für das Management von fortgeschrittenen Erkrankungen ist oft erforderlich, einschließlich Chemotherapie, Strahlentherapie, Salvage-Operation, Metastatektomie und Palliativversorgung. Trotz eines solchen Ansatzes sind metastasierende UTUC selten heilbar, und somit besteht ein großer Bedarf für neue Ansätze und Therapeutika.

Die Therapie des Urothelkarzinoms des oberen Harntraktes (UTUC) hängt in erster Linie vom Stadium und vom Grading ab. Eine Heilung lässt sich primär nur durch die chirurgische Entfernung erreichen. Zusätzlich können je nach Befund andere Methoden, wie Chemotherapie oder Radiatio adjuvant oder neoadjuvant, notwendig werden.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  • Ahmad S, Aboumarzouk O, Somani B, Nabi G, Kata SG (2012) Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit. BJU Int 110(11 Pt B):E596–E600

    Article  CAS  PubMed  Google Scholar 

  • Andersen JR, Kristensen JK (1994) Ureteroscopic management of transitional cell tumors. Scand J Urol Nephrol 28:153–157

    Article  CAS  PubMed  Google Scholar 

  • Aravantinos E, Anagnostou T, Karatzas AD et al (2007) Percutaneous nephrostomy in patients with tumors of advanced stage: treatment dilemmas and impact on clinical course and quality of life. J Endourol Endourological Soc 21:1297–1302

    Article  Google Scholar 

  • Bamias A, Deliveliotis C, Fountzilas G et al (2004a) Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the hellenic cooperative oncology group. J Clin Oncol 22:2150–2154

    Article  CAS  PubMed  Google Scholar 

  • Bamias A, Aravantinos G, Deliveliotis C et al (2004b) Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the hellenic cooperative oncology group. J Clin Oncol 22:220–228

    Article  CAS  PubMed  Google Scholar 

  • Bamias A, Dafni U, Karadimou A et al (2012) Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol

    Google Scholar 

  • Bellmunt J, Theodore C, Demkov T et al (2009a) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454–4461

    Article  CAS  PubMed  Google Scholar 

  • Bellmunt J, Choueiri TK, Fougeray R et al (2009b) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850–1855

    Article  Google Scholar 

  • Bellmunt J, von der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 30:1107–1113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bex A, Sonke GS, Pos FJ et al (2010) Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: the Netherlands Cancer Institute experience and literature review. Ann Oncol 21:2240–2245

    Article  CAS  PubMed  Google Scholar 

  • Blom JW, Doggen CJ, Osanto S et al Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA J Am Med

    Google Scholar 

  • Bolenz C, Shariat SF, Fernandez MI et al (2009) Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int 103:302–306

    Article  PubMed  Google Scholar 

  • Brien JC, Shariat SF, Herman MP et al (2010) Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 184:69–73

    Article  PubMed  Google Scholar 

  • Busby JE, Brown GA, Tamboli P et al (2006) Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 67:518–523

    Article  PubMed  Google Scholar 

  • Carles J, Suarez C, Mesia C et al (2006) Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function. Clin Transl Oncol 8:755–757

    Article  CAS  PubMed  Google Scholar 

  • Chen GL, Bagley DH (2000) Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 164:1173–1176

    Article  CAS  PubMed  Google Scholar 

  • Cho KS, Joung JY, Seo HK, et al (2010) Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cancer Chemother Pharmaco

    Google Scholar 

  • Choueiri TK, Ross RW, Jacobus S et al (2012) Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 30:507–512

    Article  CAS  PubMed  Google Scholar 

  • Chromecki TF, Cha EK, Fajkovic H et al (2012) The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253

    Article  PubMed  Google Scholar 

  • Chung SY, Stein RJ, Landsittel D et al (2004) 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 172:592–595

    Article  PubMed  Google Scholar 

  • Cornu JN, Rouprêt M, Carpentier X, Geavlete B, de Medina SG, Cussenot O, Traxer O (2010) Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 28(2):151–156

    Article  PubMed  Google Scholar 

  • Cutress ML, Stewart GD, Wells-Cole S, Phipps S, Thomas BG, Tolley DA (2012) Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. doi:10.1111/j.1464-410X.2012.11169.x

    Google Scholar 

  • Daneshmand S, Quek ML, Huffman JL (2003) Endoscopic management of upper urinary tract transitional cell carcinoma:long-term experience. Cancer 98:55–60

    Article  PubMed  Google Scholar 

  • Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506–513

    Article  CAS  PubMed  Google Scholar 

  • De Santis M, Bellmunt J, Mead G et al (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol: Off J Am Soc Clin Oncol 30:191–199

    Article  Google Scholar 

  • Dimopoulos MA, Finn L, Logothetis CJ (1994) Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 151:598–600, discussion 600–591

    CAS  PubMed  Google Scholar 

  • Eble JN, Sauter G, Epstein JI. (Hrsg) (2004) Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon

    Google Scholar 

  • Engelmyer EI, Belis JA (1996) Long-term ureteroscopic management of low-grade transitional cell carcinoma of the upper urinary tract. Tech Urol 2(2):113–116

    CAS  PubMed  Google Scholar 

  • Fajkovic H, Klatte T, Nagele U, Dunzinger M, Zigeuner R, Hübner W, Remzi M (2013) Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experience. World J Urol 31(1):37–44. doi:10.1007/s00345-012-0948-4

    Article  PubMed  Google Scholar 

  • Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ (2013) Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int 91(3):291–296

    Article  CAS  PubMed  Google Scholar 

  • Gaboardi F, Bozzola A, Dotti E, Galli L (1994) Conservative treatment of upper urinary tract tumors with Nd:YAG laser. J Endourol 8:37–41

    Article  CAS  PubMed  Google Scholar 

  • Gabrilove JL, Jakubowski A, Scher H et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422

    Article  CAS  PubMed  Google Scholar 

  • Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS (2010) Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 183(6):2148–2153

    Article  PubMed  Google Scholar 

  • Galsky MD, Iasonos A, Mironov S et al (2007) Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 69:255–259

    Article  PubMed  Google Scholar 

  • Galsky MD, Hahn NM, Rosenberg J et al (2011) Treatment of patients with metastatic urothelial cancer „unfit“ for Cisplatin-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 29:2432–2438

    Article  Google Scholar 

  • Ghoneim IA, Miocinovic R, Stephenson AJ et al (2011) Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder. Urology 77:867–870

    Article  PubMed  Google Scholar 

  • Grasso M, Fishman AI, Cohen J, Alexander B (2012) Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int. doi:10.1111/j.1464-410X.2012.11066.x

    Google Scholar 

  • Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866

    Article  CAS  PubMed  Google Scholar 

  • Guo CC, Tamboli P, Czerniak B (2009) Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases. Arch Pathol Lab Med 133:62–66

    PubMed  Google Scholar 

  • Hellenthal NJ, Shariat SF, Margulis V et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the upper tract urothelial carcinoma collaboration. J Urol 182:900–906

    Article  PubMed  Google Scholar 

  • Hensley ML, Hagerty KL, Kewalramani T et al (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol Off J Am Soc Clin Oncol 27:127–145

    Article  CAS  Google Scholar 

  • Holmang S, Lele SM, Johansson SL (2007) Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol 178:51–56

    Article  PubMed  Google Scholar 

  • Iborra I, Solsona E, Casanova J, Ricós JV, Rubio J, Climent MA (2003) Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol 169(1):82–85

    Article  CAS  PubMed  Google Scholar 

  • Igawa M, Urakami S, Shiina H et al (1995) Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 55:74–77

    Article  CAS  PubMed  Google Scholar 

  • Johnson GB, Fraiman M, Grasso M (2005) Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. BJU Int 95(suppl2):110–113

    Google Scholar 

  • Kaag MG, O'Malley RL, O'Malley P et al (2010a) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581–587

    Article  PubMed  PubMed Central  Google Scholar 

  • Kaag MG, O'Malley RL, O'Malley P et al (2010b) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581–587

    Article  PubMed  PubMed Central  Google Scholar 

  • Kastritis E, Dimopoulos MA, Antoniou N et al (2006) The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res 26:3865–3869

    CAS  PubMed  Google Scholar 

  • Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Segura JW, Zincke H, Elliott DS, Blute ML (2007) Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol 177(5):1721–1726

    Article  PubMed  Google Scholar 

  • Lane BR, Smith AK, Larson BT et al (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116:2967–2973

    Article  PubMed  Google Scholar 

  • Langner C, Hutterer G, Chromecki T et al (2006) Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J Urol 176:910–913, discussion 913-4

    Article  PubMed  Google Scholar 

  • Lehmann J, Suttmann H, Kovac I et al (2007) Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol 51:1281–1288

    Article  PubMed  Google Scholar 

  • Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073

    PubMed  Google Scholar 

  • Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055

    CAS  PubMed  Google Scholar 

  • Lucas SM, Svatek RS, Olgin G, Arriaga Y, Kabbani W, Sagalowsky AI, Lotan Y (2008) Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int 102:172–176

    Article  PubMed  Google Scholar 

  • Lughezzani G, Jeldres C, Isbarn H et al (2009) Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 45:3291–3297

    Article  PubMed  Google Scholar 

  • Lyman GH, Khorana AA, Kuderer NM et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J

    Google Scholar 

  • Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233

    Article  PubMed  Google Scholar 

  • Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127–3134

    Article  PubMed  Google Scholar 

  • Matsuoka K, Lida S, Tomiyasu K, Inoue M, Noda S (2003) Transurethral endoscopic treatment of upper urinary tract tumors using a holmium:YAG laser. Lasers Surg Med 32:336–340

    Article  PubMed  Google Scholar 

  • Painter DJ, Denton K, Timoney AG, Keeley FX (2008) Ureteroscopic management of upper-tract urothelial cancer: an exciting nephron-sparing option or an unacceptable risk? J Endourol 22(6):1237–1239

    Article  PubMed  Google Scholar 

  • Pak RW, Moskowitz EJ, Bagley DH (2009) What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol 23(3):341–346

    Article  PubMed  Google Scholar 

  • Porten S, Siefker-Radtke A, Kamat A, Dinney C, Matin S (2013) Survival outcomes in patients undergoing neoadjuvant chemotherpay for upper tract urothelial cell carcinoma. J Clin Oncol (Suppl 6:Abstr 31)

    Google Scholar 

  • Reisiger K, Hruby G, Clayman RV, Landman J (2007) Office-based surveillance ureteroscopy after endoscopic treatment of transitional cell carcinoma: technique and clinical outcome. Urology 70:263–266

    Article  PubMed  Google Scholar 

  • Rink M, Robinson BD, Green DA et al (2012) Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol 188:398–404

    Article  PubMed  Google Scholar 

  • Rouprêt M, Hupertan V, Traxer O, Loison G, Chartier-Kastler E, Conort P, Bitker MO, Gattegno B, Richard F, Cussenot O (2006) Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 67(6):1181–1187

    Article  PubMed  Google Scholar 

  • Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bohle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF, European Association of Urology (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63(6):1059

    Article  PubMed  Google Scholar 

  • Schmeller NT, Hofstetter AG (1989) Laser treatment of ureteral tumors. J Urol 141(4):840–843

    CAS  PubMed  Google Scholar 

  • Scosyrev E, Messing EM (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? BJU Int 108:700

    Article  PubMed  Google Scholar 

  • Siefker-Radtke AO, Millikan RE, Tu SM et al (2002) Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20:1361–1367

    Article  CAS  PubMed  Google Scholar 

  • Siefker-Radtke AO, Gee J, Shen Y et al (2003) Multimodality management of urachal carcinoma: the M, D Anderson Cancer Center experience. J Urol 169:1295–1298

    Article  PubMed  Google Scholar 

  • Siefker-Radtke AO, Walsh GL, Pisters LL et al (2004) Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171:145–148

    Article  PubMed  Google Scholar 

  • Siefker-Radtke A, Kamat A, Corn P, Matin S, Grossman HB, Millikan R, Dinney C (2012) Neoadjuvant chemotherapy with DDMVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. J Clin Oncol 30:Abstr 261

    Google Scholar 

  • Siefker-Radtke AO, Dinney CP, Shen Y et al (2013) A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119:540–547

    Article  CAS  PubMed  Google Scholar 

  • Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol 24:3187–3205

    Article  CAS  Google Scholar 

  • Sonpavde G, Watson D, Tourtellott M et al (2012) Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer 10:1–5

    Article  PubMed  Google Scholar 

  • Sternberg CN, Yagoda A, Scher HI et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403–407

    CAS  PubMed  Google Scholar 

  • Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646

    CAS  PubMed  Google Scholar 

  • Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50–54

    Article  CAS  PubMed  Google Scholar 

  • Sweeney CJ, Roth BJ, Kabbinavar FF et al (2006) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24:3451–3457

    Article  CAS  PubMed  Google Scholar 

  • Tawfiek ER, Bagley DH (1997) Upper-tract transitional cell carcinoma. Urology 50:321–329

    Article  CAS  PubMed  Google Scholar 

  • Traxer O, Geavlete B, de Medina SG, Sibony M, Al-Qahtani SM (2011) Narrow-band imaging digital flexible ureteroscopy in detection of upper urinary tract transitional-cell carcinoma: initial experience. J Endourol 25(1):19–23

    Article  PubMed  Google Scholar 

  • Tsao CK, Moshier E, Seng SM et al (2012) Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clin Genitourin Cancer 10:15–20

    Article  PubMed  Google Scholar 

  • Vassilakopoulou M, de la Motte Rouge T, Colin P et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer

    Google Scholar 

  • von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

    PubMed  Google Scholar 

  • Youssef RF, Shariat SF, Lotan Y et al (2011) Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the upper tract urothelial carcinoma collaboration. BJU Int 108:1286–1291

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Landesklinikum Korneuburg, Wiener Ring 3-5, 2100, Korneuburg, Österreich

    Mesut Remzi

  2. Tübingen, Deutschland

    Christian Schwentner

  3. Universitätsklinik für Urologie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich

    Shahrokh Shariat & Bernhard Grubmüller

Authors
  1. Mesut Remzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Schwentner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shahrokh Shariat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernhard Grubmüller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mesut Remzi .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Mannheim, Klinik für Urologie, Mannheim, Baden-Württemberg, Germany

    Maurice Stephan Michel

  2. Klinik für Urologie, Universitätsklinik Mannheim, Mainz, Germany

    Joachim W. Thüroff

  3. Abt. für Urologie, Universitätsklinikum Salzburg, Salzburg, Austria

    Günther Janetschek

  4. Klinik und Poliklinik für Urologie, Univer Tech Univ Dresden, Dresden, Germany

    Manfred Wirth

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Remzi, M., Schwentner, C., Shariat, S., Grubmüller, B. (2016). Urothelkarzinom der Nieren und Harnleiter: Therapie. In: Michel, M., Thüroff, J., Janetschek, G., Wirth, M. (eds) Die Urologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39940-4_70

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39940-4_70

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39939-8

  • Online ISBN: 978-3-642-39940-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation